ATA-190 is under clinical development by Atara Biotherapeutics and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase II drugs for Nasopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ATA-190 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ATA-190 overview
ATA-190 is under development for the treatment of metastatic EBV-associated nasopharyngeal carcinoma. The therapeutic candidate is administered through an intravenous route. The therapy uses autologous peripheral blood mononuclear cells which are infected with the recombinant adenoviral vector AdE1-LMPpoly which encodes multiple CD8 T cell epitopes from the EBV latent proteins such as Epstein-Barr virus nuclear antigen 1 (EBNA1) and latent membrane protein (LMP1 and LMP2). It was under development for the treatment of primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS).
See Also:
Atara Biotherapeutics overview
Atara Biotherapeutics (Atara) is a biopharmaceutical company specialized in T-cell immunotherapy. The company uses its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. It is evaluating its lead candidate, tabelecleucel in Phase III clinical trials for the treatment of Epstein Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following hematopoietic cell transplant and solid organ transplant in patients who refracted rituximab. Its pipeline product candidates that are being developed for multiple indications in various stages of clinical trials include ATA188, ATA2271, ATA3219, ATA3271 and other CAR T programs. Atara is headquartered in South San Francisco, California, the US.
For a complete picture of ATA-190’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
